...out of options.” For previously treated NSCLC, a docetaxel...

...of Sanofi (Euronext:SAN; NASDAQ:SNY), announced a collaboration to advance clinical studies of KN026 plus Taxotere docetaxel...

...mtDNA) released from prostate cancer cells could treat prostate cancer and enhance the efficacy of docetaxel...
...antagonist tool compound or fibroblast-specific TLR9 knockout reduced tumor growth. The C3AR1 antagonist also resensitized docetaxel-resistant...
...cancer cells co-cultured with CAFs, and reduced tumor growth in a xenograft mouse model of docetaxel-resistant...

...event associated with Bcl-XL inhibition. In xenograft mouse models of TNBC and SLCL, DT2216 plus docetaxel...

...checkpoint inhibitors such as Opdivo nivolumab have shown response rates of 20%; chemotherapies such as docetaxel...

...predictions in mice with breast tumors rendered tolerant to anthracyclines via treatment with the taxane docetaxel...

...diseases with poor prognoses. In one abstract, the FDA authors find they can switch the docetaxel...

...$71.3 million in cash and a 12-month operating loss of $65.6 million. MM-310 is a docetaxel...

...and Co. (NYSE:LLY) drug is already approved in the U.S. and EU in combination with docetaxel...

...Inc. (NYSE:PFE) / Clovis Oncology Inc. (NASDAQ:CLVS) Rubraca rucaparib Ph III Monotherapy Zytiga, Xtandi or docetaxel...
...testing Merck & Co.’s Keytruda pembrolizumab in combination with Xtandi, PARP inhibitor Lynparza olaparib, or docetaxel...
...were underwhelming. ORRs were 20% in combination with Xtandi, 7% with Lynparza and 14% with docetaxel...